Ruth Geraldes
Wexham Park Hospital
Slough, ENG, United Kingdom
Slough, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.
Journal: Health technology assessment (Winchester, England)
Published: June 29, 2026
Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 07, 2026
Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Journal: Annals of clinical and translational neurology
Published: March 08, 2026
Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis.
Journal: Neurology and therapy
Published: March 05, 2026
Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.
Journal: Journal of neurology
Published: January 15, 2026
Optimal strategies for treatment discontinuation in MOG antibody-associated disease.
Journal: Brain : a journal of neurology
Published: September 03, 2025
Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis.
Journal: Neurology
Published: August 20, 2025
Quantitative analysis of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies titres: correlation with relapses.
Journal: Brain communications
Published: May 29, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 23, 2025
Smoking status and vascular risk factors as predictors of disability in AQP4-NMOSD and MOGAD.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 15, 2025
The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD.
Journal: Journal of neurology
Published: January 13, 2025
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
Journal: Neurology
Published: December 12, 2024
Last Updated: 09/26/2026